Come up with a name for your new list and we'll add to it:
Satsuma Pharmaceuticals raised a round of funding on December 19, 2016. Investors include
Shin Nippon Biomedical Laboratories.
Satsuma Pharmaceuticals develops best-in-class therapies to address the unmet needs of migraine sufferers. The company's lead product candidate STS101 is a potential best-in-class therapy for migraine…